REVEL_2: REVEL, figure 2

In raredd/kmdata: A Database of Reconstructed Individual Patient Level Data from Oncology Clinical Trials

REVEL, figure 2

Description

Kaplan-Meier digitized data from REVEL, figure 2 (PMID 24933332). A reported sample size of 1,825 for a primary endpoint of OS in lung cancer.

Usage

REVEL_2

Format

A data frame of 1,253 observations and 3 variables:

	time	event time (in months)
	event	OS event indicator (0: no event, 1: event)
	arm	treatment arms (placebo_docetaxel, ramucirumab_docetaxel)

Source

Garon EB, Ciuleanu T-E, Arrieta O, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet 2014; 384: 665–73.

Examples

summary(REVEL_2)

kmplot(REVEL_2)

raredd/kmdata documentation built on June 15, 2025, 9:33 a.m.